Detalhe da pesquisa
1.
Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab.
Ann Hematol
; 100(11): 2689-2698, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34398258
2.
Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative.
Intern Med J
; 49(5): 578-591, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30414226
3.
Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.
Blood Cells Mol Dis
; 68: 153-159, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27839979
4.
Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials.
Am J Hematol
; 90(7): 584-91, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25801797
5.
Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
Am J Hematol
; 88(3): 166-71, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23386328
6.
Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
Am J Hematol
; 88(3): 179-84, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23400823
7.
Diagnostic significance of flow cytometry scales in diagnostics of myelodysplastic syndromes.
Cytometry B Clin Cytom
; 100(3): 312-321, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33052634